News & Updates
Filter by Specialty:
Pfizer/BioNTech shots effective in IBD patients
The Pfizer-BNT162b2 vaccine for the coronavirus disease 2019 (COVID-19) effectively reduces the risk of serious outcomes and hospitalization in patients with inflammatory bowel diseases (IBD), though with slight variance in effectivity with respect to ongoing medications, reports a Qatar study presented at the recently concluded 2022 Crohn’s & Colitis Congress (CCC 2022).
Pfizer/BioNTech shots effective in IBD patients
10 Feb 2022
Postinfection IBS common after C. difficile infection
A recent systematic review and meta-analysis has found that more than one in five patients develop postinfection irritable bowel syndrome (PI-IBS) following Clostridioides difficile infection (CDI).
Postinfection IBS common after C. difficile infection
09 Feb 2022
Pandemic fuels mental distress, gastric problems in IBS patients with anxiety/depression
The COVID-19 pandemic has contributed to self-reported increases in psychological distress and gastrointestinal symptoms among individuals with irritable bowel syndrome (IBS) and comorbid anxiety and/or depression, reveals a study.
